Fredun Pharmaceuticals (NSE:FREDUN) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:FREDUN Fredun Pharmaceuticals Ltd NSE:FREDUN
60 GF Score
Price ₹1,428.00
GF Value ₹600.96
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Fredun Pharmaceuticals Cyclically Adjusted Revenue per Share?

Fredun Pharmaceuticals NSE:FREDUN 60 Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:FREDUN with a GF Score™ of 60/100 and a GF Value™ of ₹600.96 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fredun Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹128.284. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Fredun Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 24.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 22.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Fredun Pharmaceuticals was 22.90% per year. The lowest was 22.80% per year. And the median was 22.85% per year.

As of today (2026-08-20), Fredun Pharmaceuticals's current stock price is ₹1428.00. Fredun Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹0.00. Fredun Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fredun Pharmaceuticals was 7.13. The lowest was 1.31. And the median was 2.56.


Fredun Pharmaceuticals  (NSE:FREDUN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fredun Pharmaceuticals was 7.13. The lowest was 1.31. And the median was 2.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fredun Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Fredun Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fredun Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fredun Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Fredun Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fredun Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:FREDUN vs : Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fredun Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fredun Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


NSE:FREDUN
60GF Score
Fredun Pharmaceuticals Ltd NSE:FREDUN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fredun Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fredun Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=128.284/333.9520*333.9520
=128.284

Current CPI (Jun. 2026) = 333.9520.

Fredun Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 14.647 241.428 20.260
201612 17.503 241.432 24.210
201703 22.961 243.801 31.451
201706 12.848 244.955 17.516
201709 16.915 246.819 22.886
201712 15.383 246.524 20.838
201803 19.447 249.554 26.024
201806 15.814 251.989 20.958
201809 18.132 252.439 23.987
201812 21.942 251.233 29.166
201903 31.089 254.202 40.842
201906 23.775 256.143 30.997
201909 26.262 256.759 34.158
201912 21.896 256.974 28.455
202003 22.362 258.115 28.932
202006 10.991 257.797 14.238
202009 26.772 260.280 34.350
202012 37.676 260.474 48.304
202103 34.332 264.877 43.285
202106 37.315 271.696 45.865
202109 45.398 274.310 55.269
202112 39.924 278.802 47.821
202203 49.840 287.504 57.892
202206 36.027 296.311 40.604
202209 51.751 296.808 58.227
202212 57.354 296.797 64.534
202303 50.074 301.836 55.402
202306 44.529 305.109 48.738
202309 57.961 307.789 62.888
202312 61.901 306.746 67.391
202403 83.148 312.332 88.904
202406 55.009 314.175 58.472
202409 75.457 315.301 79.921
202412 71.871 315.605 76.049
202503 116.752 319.799 121.919
202506 84.300 322.561 87.277
202509 101.388 324.800 104.245
202512 112.894 324.054 116.342
202603 118.542 330.213 119.884
202606 128.284 333.952 128.284

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Fredun Pharmaceuticals (NSE:FREDUN) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fredun Pharmaceuticals and its competitors.
Is Fredun Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Fredun Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Fredun Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ?
Fredun Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fredun Pharmaceuticals and its competitors. Fredun Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (NSE:FREDUN) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹600.96, compared to a current price of ₹1,428.00 — trading 137.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹0.00. Fredun Pharmaceuticals' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fredun Pharmaceuticals (NSE:FREDUN), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fredun Pharmaceuticals (NSE:FREDUN) Overvalued in 2026?

Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued. The current stock price of ₹1,428.00 is trading 137.6% above its estimated GF Value™ of ₹600.96. GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:FREDUN:

  • Cyclically Adjusted Revenue per Share: ₹0.00
  • GF Value™: ₹600.96 vs. price of ₹1,428.00 (137.6% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the NSE:FREDUN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fredun Pharmaceuticals Business Description

Comparable Companies
Other Exchanges 539730:India
Address Ganpatrao Kadam Marg, Delisle Road, 11th Floor, Urmi Estate 95, Lower Parel (West), Mumbai, MH, IND, 400013
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
60GF Score

Get the complete analysis for NSE:FREDUN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,428.00
Price
₹600.96
GF Value